Hanneke Schuitemaker

Active 1988–2025

139
Papers
25,262
Citations
88
h-index
135
i10-index

Citations

Citations per year for Hanneke Schuitemaker1989: 3 citations1990: 3 citations1991: 6 citations1992: 22 citations1993: 53 citations1994: 78 citations1995: 67 citations1996: 89 citations1997: 136 citations1998: 154 citations1999: 172 citations2000: 138 citations2001: 142 citations2002: 125 citations2003: 106 citations2004: 94 citations2005: 112 citations2006: 85 citations2007: 79 citations2008: 77 citations2009: 74 citations2010: 95 citations2011: 109 citations2012: 112 citations2013: 111 citations2014: 71 citations2015: 79 citations2016: 133 citations2017: 153 citations2018: 137 citations2019: 441 citations2020: 565 citations2021: 1,721 citations2022: 1,288 citations2023: 512 citations2024: 616 citations2025: 214 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,437 citing papers, 34.4% of this breakdownUnited Kingdom: 719 citing papers, 7.2% of this breakdownNetherlands: 533 citing papers, 5.3% of this breakdownChina: 430 citing papers, 4.3% of this breakdownGermany: 378 citing papers, 3.8% of this breakdownFrance: 374 citing papers, 3.7% of this breakdownCanada: 331 citing papers, 3.3% of this breakdownItaly: 286 citing papers, 2.9% of this breakdownBelgium: 235 citing papers, 2.4% of this breakdownSouth Africa: 230 citing papers, 2.3% of this breakdownAustralia: 221 citing papers, 2.2% of this breakdownSpain: 206 citing papers, 2.1% of this breakdown
0%34.4%Other 26.1%

Fields

  • Medicine50%
  • Immunology and Microbiology39.5%
  • Biochemistry, Genetics and Molecular Biology6.9%
  • Social Sciences1.2%
  • Agricultural and Biological Sciences0.4%
  • Mathematics0.4%
  • Other1.6%

Topics

  • HIV Research and Treatment13.5%
  • SARS-CoV-2 and COVID-19 Research12.3%
  • Immune Cell Function and Interaction6.2%
  • COVID-19 Clinical Research Studies5.7%
  • HIV/AIDS drug development and treatment4.5%
  • HIV/AIDS Research and Interventions3.4%
  • Other54.4%

Coauthors

All papers

Open in search
  1. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 2,601

  2. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism

    Authors: , , , , , , , , , , - Nature Communications 2015 cited by 387

  3. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 250

  4. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 1,184

  5. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frances Priddy, Erica Lazarus, Fatima Laher, Sorachai Nitayapan, Punnee Pitisuttithum, Stephan Bart, Thomas Campbell, Robert Feldman, Gregg Lucksinger, Caroline Borremans, Katleen Callewaert, Raphaele Roten, Jerald Sadoff, Lorenz Scheppler, Mo Weijtens, Karin Feddes-de Boer, Daniëlle van Manen, Jessica Vreugdenhil, Roland Zahn, Ludo Lavreys, Steven Nijs, Jeroen Tolboom, Jenny Hendriks, Zelda Euler, Maria Grazia Pau, Hanneke Schuitemaker - The Lancet 2018 cited by 342

  6. Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies

    Authors: , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2012 cited by 581

  7. Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cell 2015 cited by 371

  8. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Makda S. Gebre, Emily Hoffman, Catherine Jacob-Dolan, Marinela Kirilova, Zhenfeng Li, Zijin Lin, Shant H. Mahrokhian, Lori F. Maxfield, Felix Nampanya, Ramya Nityanandam, Joseph P. Nkolola, Shivani Patel, John D. Ventura, Kaylee Verrington, Huahua Wan, Laurent Pessaint, Alex Van Ry, Kelvin Blade, Amanda Strasbaugh, Mehtap Cabus, Renita Brown, Anthony Cook, Serge Zouantchangadou, Elyse Teow, Hanné Andersen, Mark G. Lewis, Yongfei Cai, Bing Chen, Aaron G. Schmidt, R. Keith Reeves, Ralph S. Baric, Douglas A. Lauffenburger, Galit Alter, Paul Stoffels, Mathai Mammen, Johan Van Hoof, Hanneke Schuitemaker, Dan H. Barouch - Nature 2020 cited by 907

  9. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, Avi Kenny, Marco Carone, Daniel Wolfe, Jerald Sadoff, Glenda Gray, Beatriz Grinsztejn, Paul Goepfert, Susan J. Little, Leonardo Paiva de Sousa, Rebone Maboa, April K. Randhawa, Michele P. Andrasik, Jenny Hendriks, Carla Truyers, Frank Struyf, Hanneke Schuitemaker, Macaya Douoguih, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Lindsay N. Carpp, Dean Follmann, Peter B. Gilbert, Richard A. Koup, Rubén O. Donis, on behalf of the Immune Assays Team, the Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team, and the United States Government (USG)/CoVPN Biostatistics Team - Nature Microbiology 2022 cited by 93

  10. Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rogier W. Sanders - Cell 2015 cited by 380

  11. Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2016 cited by 330

  12. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dimitri Goedhart, Michael C. Keefer, Colleen Kelly, Ken Mayer, Joseph P. Nkolola, Lauren Peter, Merlin L. Robb, Nadine Rouphael, Lorenz Scheppler, Magda Sobieszczyk, Hong‐Van Tieu - The Lancet HIV 2020 cited by 91

  13. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

    Authors: , , , , , , , , , , , - The Journal of Infectious Diseases 2020 cited by 111

  14. Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study

    Authors: , , , , , , , , , , , , , , , , - The Journal of Infectious Diseases 2021 cited by 90

  15. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fei Chen, Polan Chetty, Pei-Ling Chu, Kimberly L. Cooper, Jerome Custers, Hilde Delanghe, A. Duca, Tracy Henrick, Jarek Juraszek, Catherine Nalpas, Monika Peeters, José Cirı́aco Pinheiro, Sanne Roels, Martin Ryser, José A. Salas, Samantha Santoro Matias, Ilse Scheys, Pallavi Shetty, Georgi Shukarev, Jeffrey J. Stoddard, Willem Talloen, NamPhuong Tran, Nathalie Vaissière, Elisabeth van Son-Palmen, Jiajun Xu, Erin A. Goecker, Alexander L. Greninger, Keith R. Jerome, Pavitra Roychoudhury, Simbarashe Takuva, J.L. Mendoza, Eric D. Achtyes, Habibul Ahsan, Azhar Alhatemi, Nancy A. Allen, José Ramón Arribas, Ghazaleh Bahrami, Lucía Bailón, Ali Ahsan Bajwa, Jonathan Baker, Mira Baron, Susana Benet, Driss Berdaï, Patrick Berger, Todd Bertoch, Claire Bethune, Sybille Bevilacqua, Maria Silvia Biagioni Santos, Ian Binnian, Karen Bisnauthsing, Jean‐Marc Boivin, Hilde Bollen, Sandrine Bonnet, Alberto M. Borobia, Élisabeth Botelho-Nevers, Phil Bright, Vianne Britten, Claire Brown, Amanda Buadi, Erik Buntinx, Lesley Burgess, Larry M. Bush, María Rosario Capeding, Quito Osuna Carr, Amparo Carrasco Mas, Hélène Catalá, Katrina Cathie, T S Caudill, Fernando Cereto Castro, Kénora Chau and 190 more - The Lancet Infectious Diseases 2022 cited by 88

  16. Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susan Buchbinder, Trevor A. Crowell, Zelda Euler, Ian Frank, Dimitri Goedhart, Jennifer Johnson, Michael C. Keefer, Colleen F. Kelley, Kenneth H. Mayer, Joseph P. Nkolola, Lauren Peter, Merlin L. Robb, Nadine Rouphael, Lorenz Scheppler, Magda Sobieszczyk, Hong‐Van Tieu, Matthew H. Collins, Varun K. Phadke - The Journal of Infectious Diseases 2022 cited by 36

  17. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2016 cited by 272

  18. Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 256

  19. A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers

    Authors: , , , , , , , , , , , , - Cell Reports 2018 cited by 116

  20. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Diane G. Kanjilal, Caitlin J. Guiney, Connor Bradshaw, Anna L. Tyler, Tatenda Makoni, Katherine E. Yanosick, Michael S. Seaman, Douglas A. Lauffenburger, Galit Alter, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker, Dan H. Barouch - JAMA 2021 cited by 336

  21. Inactivated Viral Vaccines

    Authors: , , - Vaccine Analysis: Strategies, Vaccine Analysis: Strategies, Principles, and Control 2014 cited by 162

  22. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

    Authors: , , , , , , , , , , , , , , , , , , , , - PLoS ONE 2018 cited by 94

  23. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - npj Vaccines 2020 cited by 74

  24. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nelson Michael, Merlin L. Robb, Frank Tomaka, Jintanat Ananworanich - Nature Medicine 2020 cited by 72